Champions Oncology (CSBR) Shares Outstanding (Weighted Average) (2016 - 2026)
Champions Oncology has reported Shares Outstanding (Weighted Average) over the past 16 years, most recently at $13.8 million for Q1 2026.
- Quarterly results put Shares Outstanding (Weighted Average) at $13.8 million for Q1 2026, up 0.77% from a year ago — trailing twelve months through Jan 2026 was $13.8 million (up 0.77% YoY), and the annual figure for FY2025 was $13.7 million, up 0.83%.
- Shares Outstanding (Weighted Average) for Q1 2026 was $13.8 million at Champions Oncology, roughly flat from $13.8 million in the prior quarter.
- Over the last five years, Shares Outstanding (Weighted Average) for CSBR hit a ceiling of $13.8 million in Q1 2026 and a floor of $13.2 million in Q1 2022.
- Median Shares Outstanding (Weighted Average) over the past 5 years was $13.6 million (2023), compared with a mean of $13.6 million.
- Biggest five-year swings in Shares Outstanding (Weighted Average): dropped 1.5% in 2022 and later increased 2.94% in 2023.
- Champions Oncology's Shares Outstanding (Weighted Average) stood at $13.5 million in 2022, then fell by 0.18% to $13.5 million in 2023, then increased by 0.72% to $13.6 million in 2024, then increased by 1.46% to $13.8 million in 2025, then grew by 0.1% to $13.8 million in 2026.
- The last three reported values for Shares Outstanding (Weighted Average) were $13.8 million (Q1 2026), $13.8 million (Q4 2025), and $13.8 million (Q3 2025) per Business Quant data.